HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026

Submitted by Anonymous on

®® HONG KONG, SHANGHAI and FLORHAM PARK, N.J., Oct. 26, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces positive results from the SANOVO Phase III trial in China. ORPATHYS® (savolitinib) plus TAGRISSO® (osimertinib) demonstrated a statistically...

HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026

Submitted by Anonymous on

- ORPATHYS® plus TAGRISSO® reduced the risk of disease progression or death by 44% in the overall population and 55% in the high MET overexpression population in the first-line setting - - Robust PFS gains alongside very encouraging OS clinical...

HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026

Submitted by Anonymous on

- ORPATHYS®plus TAGRISSO®reduced the risk of disease progression or death by 44% in the overall population and 55% in the high MET overexpression population in the first-line setting - - Robust PFS gains alongside very encouraging OS clinical benefit in...

HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026

Submitted by Anonymous on

This is a paid press release. Contact the press release distributor directly with any inquiries. HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026 HUTCHMED (China) Limited Mon, October...

Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study

Submitted by Anonymous on

SystImmune, Inc. (SystImmune), a clinical stage biotechnology company, and Bristol Myers Squibb (NYSE: BMY) today announced that SystImmune’s parent company Sichuan Biokin Pharmaceutical, Ltd. (Biokin) reported positive results from a prespecified interim analysis in the randomized, multicenter Phase 3 PANKU-Lung01...

Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study

Submitted by Anonymous on

BOTHELL, Wash. & PRINCETON, N.J.--(BUSINESS WIRE)--Oct 26, 2026-- SystImmune, Inc. (SystImmune), a clinical stage biotechnology company, and Bristol Myers Squibb (NYSE: BMY) today announced that SystImmune’s parent company Sichuan Biokin Pharmaceutical, Ltd. (Biokin) reported positive results from a prespecified interim...

Primary resistance to afatinib in a patient with NSCLC harboring EGFR p.E709_T710delinsD and brain metastases: a case report and literature review

Submitted by Anonymous on

Abstract EGFR p.E709_T710delinsD is a rare in-frame deletion-insertion P-loop and alpha-C-helix compressing (PACC) mutation of EGFR exon 18. Current evidence suggests that patients with non-small cell lung cancer (NSCLC) harboring this variant generally respond to afatinib. However, primary resistance to...

Prolonged survival after small-cell transformation of EGFR-mutant lung adenocarcinoma: a case report

Submitted by Anonymous on

Abstract Transformed small cell lung cancer (T-SCLC) is most commonly observed in EGFR-mutant lung adenocarcinoma and represents an important mechanism of acquired resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs). Its reported clinical incidence is approximately 3%-10%. Patients with T-SCLC often...

SAFFRON Phase III: Osimertinib Plus Savolitinib Significantly Improves Progression-Free and Overall Survival in MET-Driven EGFR-Mutated NSCLC

Submitted by Anonymous on

SAFFRON Phase III: Osimertinib Plus Savolitinib Significantly Improves Progression-Free and Overall Survival in MET-Driven EGFR-Mutated NSCLC The SAFFRON phase III trial has demonstrated statistically significant improvements in both progression-free survival (PFS) and overall survival (OS) with osimertinib plus savolitinib compared...

Subscribe to Newsfeed